Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers.
Germany
NTM
best practices
interviews
management
pulmonary
treatment centers
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
22 Sep 2023
22 Sep 2023
Historique:
received:
18
04
2023
revised:
14
09
2023
accepted:
20
09
2023
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic inflammatory lung disease caused by infection with non-tuberculous mycobacteria (NTM). International guidelines provide evidence-based recommendations on appropriate diagnosis and treatment strategies, but there is a need for sharing day-to-day best practice between treatment centers to optimize patient care. This is particularly valuable for rare diseases like NTM-PD. In this cross-sectional analysis of NTM-PD management in Germany, medical and administrative staff from seven treatment centers were interviewed to identify best practice in the diagnosis, treatment, and ongoing management of patients with NTM-PD, including related hospital infrastructure and administration processes. A prioritization led to a collection of best practices for the management of patients with NTM-PD in Germany, which is presented here. Selected current best practices included performance of regular sputum tests for diagnosis, use of medical reports, and regular follow-up visits as well as increased interaction between physicians across different specialties. Future best practices that may be implemented to overcome current barriers comprised disease awareness activities, patient empowerment, and new approaches to enhance physician interaction. Challenges related to their implementation are also discussed and will help to raise disease awareness. The presented best practices may guide and optimize patient management in other centers.
Identifiants
pubmed: 37830647
pii: healthcare11192610
doi: 10.3390/healthcare11192610
pmc: PMC10572995
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CSRD VA
ID : 1
Pays : United States
Références
Respir Med. 2015 Jan;109(1):137-45
pubmed: 25464905
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33542057
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36
pubmed: 32628747
ERJ Open Res. 2021 Feb 15;7(1):
pubmed: 33614773
Ther Adv Med Oncol. 2022 Oct 31;14:17588359221127681
pubmed: 36339928
Emerg Infect Dis. 2016 Jun;22(6):1102-5
pubmed: 27191473
Patient Prefer Adherence. 2016 Apr 28;10:711-25
pubmed: 27175071
Life (Basel). 2023 Apr 10;13(4):
pubmed: 37109507
Curr Pulmonol Rep. 2018 Dec;7(4):126-132
pubmed: 31106117
PLoS One. 2017 Nov 20;12(11):e0188348
pubmed: 29155870
Adv Ther. 2020 Jun;37(6):2999-3009
pubmed: 32333326
J Korean Med Sci. 2016 May;31(5):649-59
pubmed: 27134484
Eur Respir J. 2020 Oct 1;56(4):
pubmed: 32430411
J Appl Microbiol. 2009 Aug;107(2):356-67
pubmed: 19228258
Thorax. 2009 Jun;64(6):502-6
pubmed: 19213773
BMC Infect Dis. 2018 May 3;18(1):206
pubmed: 29724184
Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1909-18
pubmed: 26155783
Respir Med. 2011 Nov;105(11):1718-25
pubmed: 21868209
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Respir Med. 2020 Nov;173:106164
pubmed: 32992265
Br J Radiol. 2020 Feb 1;93(1106):20190768
pubmed: 31794241
Eur Respir J. 2017 Feb 15;49(2):
pubmed: 28182571
Thorax. 2007 Aug;62(8):661-6
pubmed: 17311842
Am J Respir Crit Care Med. 2015 Sep 1;192(5):618-28
pubmed: 26038974
J Clin Tuberc Other Mycobact Dis. 2020 Aug 06;20:100178
pubmed: 32802970
Br J Cancer. 2015 Jan 6;112(1):207-16
pubmed: 25461805
Internist (Berl). 2022 Mar;63(3):255-265
pubmed: 35181796
Am J Respir Crit Care Med. 2012 Sep 15;186(6):553-8
pubmed: 22773732
Pneumologie. 2013 Nov;67(11):605-33
pubmed: 24198237
Clin Microbiol Rev. 2004 Jan;17(1):98-106
pubmed: 14726457
BMJ Open Respir Res. 2020 Jun;7(1):
pubmed: 32565445
Int J Infect Dis. 2021 Mar;104:398-406
pubmed: 33444748